V) Revenue EBITDA Revenue EBITDA 2018 201920182019 Cara Therapeutics, Inc. NasdagGM:CARA $1245 56.3% $406.0 $303.0 $0.9 -$65.8 NM NM NM 86.1x NM NM GW Pharmaceuticals ple NasdagGM:GWPH 124.49 91% 3,153.2 2,847.7 11.0 -191.6 NM NM NM 11.4 NM NM INSYS Therapeutics, Inc. NasdaqGM:INSY 5.30 64.7% 388.6 266.9 164.1 -35.6 1